EDRONAX

This brand name is authorized in Australia, Austria, Croatia, Estonia, Ireland, Israel, New Zealand, Poland, South Africa, Turkey, UK.

Active ingredients

The drug EDRONAX contains one active pharmaceutical ingredient (API):

1	Reboxetine UNII L94J81YNNY - REBOXETINE MESYLATE
	Reboxetine is a highly selective and potent inhibitor of noradrenaline reuptake. Noradrenaline reuptake inhibition and the consequent increase of noradrenaline availability in the synaptic cleft and modification of noradrenergic transmission, reportedly is among the most relevant mechanisms of action of known antidepressant drugs.
	Read more about Reboxetine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EDRONAX Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06AX18	Reboxetine	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AX Other antidepressants
Discover more medicines within N06AX18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8583R
EE	Ravimiamet	1070930, 1640786, 1888500
GB	Medicines & Healthcare Products Regulatory Agency	142158, 161701, 22018, 373799
HR	Agencija za lijekove i medicinske proizvode	HR-H-843519291
IE	Health Products Regulatory Authority	22861
IL	מִשְׂרַד הַבְּרִיאוּת	4070
NZ	Medicines and Medical Devices Safety Authority	8169
PL	Rejestru Produktów Leczniczych	100098326
TR	İlaç ve Tıbbi Cihaz Kurumu	8681308011008
ZA	Health Products Regulatory Authority	33/1.2/0246